Mesothelioma  >>  Imjudo (tremelimumab) 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
DETERMINE, NCT01843374 / 2012-003524-21: Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Checkmark From DETERMINE trial in 2nd-line malignant mesothelioma
Jul 2017 - Jul 2017: From DETERMINE trial in 2nd-line malignant mesothelioma
Checkmark Completion of enrollment in P2 trial for malignant mesothelioma
Nov 2016 - Nov 2016: Completion of enrollment in P2 trial for malignant mesothelioma
Checkmark Of P2 DETERMINE trial in 2nd/3rd line mesothelioma due to safety/efficacy reason
More
Active, not recruiting
2
571
Europe, Canada, US, RoW
Tremelimumab, Placebo
MedImmune LLC
Unresectable Pleural or Peritoneal Malignant Mesothelioma
01/16
12/24
NCT05380713: ......SMARTEST Trial......

Recruiting
2
30
Canada
Cyclophosphamide, Tremelimumab, Durvalumab
University Health Network, Toronto, OICR
Mesothelioma, Malignant
07/25
10/28
NCT05932199: Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Not yet recruiting
1/2
52
US
Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Baylor College of Medicine, Duke Cancer Institute
Mesothelioma
05/28
05/28

Download Options